Air Fresheners; TSCA Section 21 Petition
EPA petition under TSCA Section 21 seeks to regulate air fresheners due to potential health risks. While not directly under MoCRA, this signals increased scrutiny on fragrance chemicals used in cosmetics and personal care products.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors using fragrance in air fresheners or similar products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; petition pending.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Petition filed to require EPA to regulate air fresheners under TSCA, potentially leading to restrictions on certain fragrance ingredients.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors using fragrance in air fresheners or similar products.
What you must do
Monitor EPA actions; review fragrance ingredient lists for any future restrictions.
Deadline
No immediate deadline; petition pending.
Source: https://www.federalregister.gov/documents/2007/12/21/07-6176/air-fresheners-tsca-section-21-petition
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection